SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 Map kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 11, 2000, Pages 1261-1264

  Revesz, Laszlo ^a   Di Padova, Franco E ^a   Buhl, Thomas ^a   Feifel, Roland ^a   Gram, Hermann ^a   Hiestand, Peter ^a   Manning, Ute ^a   Zimmerlin, Alfred G ^a  

^a Arthritis and Bone Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 HYDROXYPIPERIDINE HETEROCYCLE; CYTOCHROME P450 ISOENZYME; HETEROCYCLIC HYDROXY COMPOUND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROSTAGLANDIN SYNTHASE; PYRIDINYLOXAZOLE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTHRITIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0034608331     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00200-6     Document Type: Article

References (28)

1. Herlaar E., Brown Z. Molecular Medicine Today. 5:1999;439.
2. Kumar S., McDonnell P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R. Biochem. Biophys. Res. Commun. 235:1997;533.
3. Lee, J. C.; Blumenthal, M. J.; Laydon, J. T.; Tan, K. B.; DeWitt, D. L. 7th International Conference of the Inflammatory Research Association; Poconos, PA, 1994. Lin, W. W.; Chen, B. C. Br. J. Pharmacol. 1999, 126, 1419.
4. Lee, J. C.; Blumenthal, M. J.; Laydon, J. T.; Tan, K. B.; DeWitt, D. L. 7th International Conference of the Inflammatory Research Association; Poconos, PA, 1994. Lin, W. W.; Chen, B. C. Br. J. Pharmacol. 1999, 126, 1419.
5. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. J. Pharmacol. Exp. Ther. 1996, 279, 1453. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, Jerry L. Pharmacol. Ther. 1999, 82, 389.
6. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. J. Pharmacol. Exp. Ther. 1996, 279, 1453. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, Jerry L. Pharmacol. Ther. 1999, 82, 389.
7. 1: GP054086. Fitzi, K. DE 2221546, 1972; Chem. Abstr. 1972, 78, 58428.
8. Borsch-Haubold A.G., Pasquet S., Watson S.P. J. Biol. Chem. 273:1998;28766.
9. A phosphorylated form of His-p38α MAP kinase (10 ng/well) of murine origin was used and immobilised GST-ATF-2 as substrate in the presence of 120 μM cold ATP.
10. COX-1 from ram seminal vesicles (Nr. 60100; Cayman Chemical Company) was used and PGE2 determined by RIA.
11. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. J. Med. Chem. 2000, 43, 133. Lisnock, J. M.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Biochemistry 1998, 37, 16573.
12. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. J. Med. Chem. 2000, 43, 133. Lisnock, J. M.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Biochemistry 1998, 37, 16573.
13. Human peripheral blood mononuclear cells from healthy volunteers were incubated with the inhibitor and stimulated with LPS/IFN-γ for 3 h. The supernatants were collected for TNF-α determination by ELISA.
14. Eight-week old female OF1 mice were dosed perorally by gavage with solutions of the compounds in DMSO/cornoil. One hour after dosing, LPS (20 mg/kg) was injected iv for stimulation of TNF-α release into plasma. One h later blood was collected and TNF-α was determined using a mouse specific ELISA.
15. Compound 8 was dosed at 1 mg/kg iv and 20 mg/kg po. Compound 11 was dosed at 3 mg/kg iv and 10 mg/kg po.
16. Cmax: maximal plasma concentration after oral dose (8: 20 mg/kg po. 11 mg/kg po).
17. AA: adjuvant induced arthritis. Female Wistar rats were immunized with Mycobacterium tuberculosis at day 0 and dosed with the compounds (2×25 mg/kg po per day) from day 14-20. Swelling of the joints was measured on day 20.
18. CIA:collagen induced arthritis. Female (WAG×BUF/F1) rats were immunized intradermally with bovine nasal septum type II collagen emulsified in Freund's incomplete adjuvant. Compound 11 was dosed twice daily for 10 days after the onset of swelling.
19. Phosphorylated forms of His-p38β2, His-p38δ, His-JNK1 and His-JNK2 MAP kinases of human origin phosporylated the immobilised substrate GST-ATF-2 in the presence of cold ATP (120 μM). Antibody detected phosphorylated GST-ATF-2.
20. 32P)γ-ATP.
21. Crespi C.L., Miller V.P., Penman B.W. Anal. Biochem. 248:1997;188.
22. Adams J.L., Boehm J.C., Kassis S., Gorycki P.D., Webb E.F., Hall R., Sorenson M., Lee J.C., Ayrton A., Griswold D.E., Gallagher T.F. Bioorg. Med. Chem. Lett. 8:1998;3111.
23. Gallagher T.F., Seibel G.L., Kassis S., Laydon J.T., Blumenthal M.J., Lee J.C., Lee D., Boehm J.C., Fier-Thompson S.M.et al. Bioorg. Med. Chem. 5:1997;49.
24. Revesz, L. WO 9901449, 1999; Chem. Abstr. 1999, 130, 125072.
25. Bredereck H., Gompper R. Chem. Ber. 87:1954;700.
26. Severin T., Poehlmann H. Chem. Ber. 110:1977;491.
27. Teitei T. Aust. J. Chem. 33:1980;605.
28. De Laszlo, S. E.; Chang, L. L.; Kim, D.; Mantlo, Nathan B. WO 9716442, 1997; Chem. Abstr. 1997, 127, 50543.